Temple wearable device controversy intensifies as critics challenge the scientific basis for its claimed ability to monitor brain-related blood flow, while Deepinder Goyal and Temple defend the product’s purpose and pricing. The debate is driven largely by posts from hepatologist Dr Cyriac Abby Philips (TheLiverDoc), who says he and other clinical scientists found no evidence supporting what the device claims.
Multiple outlets report that Dr Philips repeatedly questions Temple’s assertions after the company begins taking pre-orders for a ₹85,000 device. The Hindu and Times of India also describe Goyal’s response, including his position that Temple is a fitness and AI tool rather than a medical device and that it should not be used to diagnose or prevent disease. Other coverage highlights what supporters and critics say the device measures and how it should be evaluated.
Across the reports, Goyal’s messaging focuses on lack of “medical claims,” willingness to rely on staged evidence, and development investment amounts. In parallel, critics and doctors press for regulatory scrutiny from the government, arguing that the device’s evidence does not match its marketing claims.
